Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
|
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase1, Phase2 |
Australia Canada Czechia Denmark France Germany Israel Italy Japan Singapore South Korea Spain Taiwan United States View all
|
NCT06726148 |
|
Phase 2 Study of Rapcabtagene Autoleucel in Myositis |
Idiopathic Inflammatory Myopathies | Phase2 |
France Germany Israel Italy Japan Netherlands Singapore Spain Taiwan United Kingdom United States View all
|
NCT06665256 |
|
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 |
Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania South Africa South Korea Spain Taiwan Thailand United States View all
|
NCT06133972 |
|
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) |
Lupus Erythematosus, Systemic, Lupus Nephritis | Phase2 |
Australia Austria Brazil Czechia Denmark France Germany Hungary Italy Japan Netherlands Norway Romania Saudi Arabia Singapore South Korea Spain Sweden Switzerland Taiwan United Kingdom United States View all
|
NCT06581198 |
|
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. |
Lymphatic Malformations | Phase2, Phase3 |
Australia Belgium France Germany Italy Netherlands Spain United States View all
|
NCT05948943 |
|
Home Reported Outcomes in PNH |
Paroxysmal Nocturnal Hemoglobinuria | United States | NCT06411626 | |
|
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever |
Dengue | Phase2 |
Brazil Colombia India Malaysia Singapore Vietnam View all
|
NCT06006559 |
|
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN |
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase2 |
Israel Malaysia United States |
NCT06797518 |
|
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas |
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer | Phase1, Phase2 |
France Italy Poland South Korea Spain United Kingdom United States View all
|
NCT04104776 |
|
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice |
Paroxysmal Nocturnal Hemoglobinuria | Russia | NCT07036718 |